European Journal of Cardiovascular Medicine

Introduction Iron deficiency anaemia during pregnancy is one of the most common and intractable nutritional problems in the world as well as in India today. Traditional treatment for anemia based on either oral iron or blood transfusion or both, has had drawbacks. Thus iron sucrose and recombinant human erythropoietin can become promising management options. Objective To assess improvement in anaemic state and the duration required for the improvement in hematological parameters with or without injection erythropoietin in pregnant females receiving iron sucrose. Method And Materials Randomized control trial was conducted on 212 anaemic pregnant women (Hb < 11 gm%) for analysing the comparison of patient response to parenteral iron sucrose alone (Group A = 104 patients) with Inj. Recombinant Human Erythropoietin (rhEPO) along with routine tab iron (Group B = 108 patients),from November 2020 to October 2022. Data related to demography, clinical history along with various blood parameters were collected, analyzed and compared between the two groups. Result Mean pre- and post-treatment Hb was 8.86 ± 0.79 gm% and 9.77 ± 0.56 gm% in group  A re. in comparison to 8.71 ± 1.06 gm% 9.79 ± 0.07 gm% in group B respectively. No significant difference was seen in rise in Hb, MCHC, serum iron and serum ferritin and fall in TIBC in treatment while significant increase in MCV, MCH within both the groups post treatment. Mean duration for improvement in Hb by 1gm% in group A was 5.850 ± 0.983 days post-treatment while 12.390 ± 1.528 days in group B. Conclusion We noticed that mean duration required for improvement in haemoglobin level by 1gm%  in group A was significantly lesser i.e. 5.850 ± 0.983 days following treatment than mean duration in group B was 12.390 ± 1.528 days ( p < 0.001).